|
11 Companies |
|
18 Products |
|
18 Products |
|
37 Mechanisms of Action |
|
0 Trials |
|
39 News |
|
- | Torisel (temsirolimus) / Pfizer
Phase classification, Metastases: A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors (clinicaltrials.gov) - Apr 17, 2018
P1, N=12, Completed, Sponsor: City of Hope Medical Center
Phase classification: P=N/A --> P1
- | NN1213 / Novo Nordisk
Trial completion: Antineoplaston Therapy in Treating Patients With Brain Tumors (clinicaltrials.gov) - Aug 22, 2017
P2, N=40, Completed, Sponsor: Burzynski Research Institute
Phase classification: P=N/A --> P1 Recruiting --> Completed
- | Enrollment change, Trial withdrawal, Trial primary completion date: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Apr 28, 2017
P=N/A, N=0, Withdrawn, Sponsor: Sue O'Dorisio
Recruiting --> Completed N=30 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Dec 2018 --> Mar 2017
- Trial primary completion date: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Sep 8, 2016
P=N/A, N=30, Suspended, Sponsor: O'Dorisio, M S
N=30 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Dec 2018 --> Mar 2017 Trial primary completion date: Jul 2016 --> Dec 2018
- Trial primary completion date: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Jun 21, 2016
P=N/A, N=30, Suspended, Sponsor: O'Dorisio, M S
Trial primary completion date: Jul 2016 --> Dec 2018 Trial primary completion date: Jul 2015 --> Jul 2016
- Trial completion, Enrollment change, Trial primary completion date: Study of Tissue Samples From Patients With Glioma or Other Brain Tumors (clinicaltrials.gov) - Nov 24, 2015
P=N/A, N=180, Completed, Sponsor: University Hospital, Montpellier
Trial primary completion date: Jul 2015 --> Jul 2016 Recruiting --> Completed | N=150 --> 180 | Trial primary completion date: Dec 2008 --> Jul 2009
- RG4733 / Roche
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Sep 29, 2015
P1, N=22, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=150 --> 180 | Trial primary completion date: Dec 2008 --> Jul 2009 Active, not recruiting --> Completed | N=34 --> 22 | Trial primary completion date: May 2017 --> Jun 2013
- Trial primary completion date: Yoga Therapy in Treating Patients With Malignant Brain Tumors (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=9, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed | N=34 --> 22 | Trial primary completion date: May 2017 --> Jun 2013 Trial primary completion date: Dec 2013 --> Sep 2012
- | emvododstat (PTC299) / PTC Therap
Trial completion, Trial primary completion date: PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors (clinicaltrials.gov) - May 4, 2015
P1, N=28, Completed, Sponsor: Pediatric Brain Tumor Consortium
Trial primary completion date: Dec 2013 --> Sep 2012 Suspended --> Completed | Trial primary completion date: May 2012 --> Jan 2015
- Trial suspension: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Apr 22, 2015
P=N/A, N=30, Suspended, Sponsor: University of Iowa
Suspended --> Completed | Trial primary completion date: May 2012 --> Jan 2015 Recruiting --> Suspended
- Trial primary completion date: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Oct 15, 2014
P=N/A, N=30, Recruiting, Sponsor: University of Iowa
Recruiting --> Suspended Trial primary completion date: Jul 2014 --> Jul 2015
- temozolomide / Generic mfg.
Trial completion: Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors (clinicaltrials.gov) - Sep 30, 2014
P=N/A, N=16, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Jul 2014 --> Jul 2015 Active, not recruiting --> Completed
- RG4733 / Roche
Trial primary completion date, Combination therapy: RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Jul 30, 2014
P1, N=34, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Jul 2014 --> May 2017
- Clinical: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=30, Recruiting, Sponsor: University of Iowa
- RG4733 / Roche
Enrollment change, Combination therapy: RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - May 29, 2014
P1, N=24, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2014 --> May 2017 N=34 --> 24
- Avastin (bevacizumab) / Roche
Enrollment change, Adverse events: Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer (clinicaltrials.gov) - Apr 20, 2014
P2, N=11, Completed, Sponsor: National Cancer Institute (NCI)
N=34 --> 24 N=16 --> 11
- | thalidomide / Generic mfg., docetaxel / Generic mfg.
Trial completion, Metastases: Thalidomide and Docetaxel in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=26, Completed, Sponsor: Case Comprehensive Cancer Center
N=16 --> 11 Active, not recruiting --> Completed
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Epigenetic controller, Metastases: MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=75, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | paclitaxel / Generic mfg.
Trial completion, Metastases: Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas (clinicaltrials.gov) - Feb 19, 2014
P1, N=70, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed No longer recruiting --> Completed
- Rytelo (imetelstat) / Geron
Enrollment change: Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma (clinicaltrials.gov) - Jan 28, 2014
P1, N=34, Completed, Sponsor: Children's Oncology Group
No longer recruiting --> Completed N=45 --> 34
- | Rytelo (imetelstat) / Geron
Trial completion: Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma (clinicaltrials.gov) - Jan 28, 2014
P1, N=34, Completed, Sponsor: Children's Oncology Group
N=45 --> 34 Active, not recruiting --> Completed
- carboplatin / Generic mfg.
Trial completion, Metastases: Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 17, 2013
P1, N=0, Completed, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Active, not recruiting --> Completed
- carboplatin / Generic mfg., thiotepa / Generic mfg.
Trial completion, Surgery: Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors (clinicaltrials.gov) - Jul 31, 2013
P2, N=50, Completed, Sponsor: Children's Cancer and Leukaemia Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- pregabalin / Generic mfg., levetiracetam / Generic mfg.
Trial completion, Monotherapy: Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors (clinicaltrials.gov) - May 20, 2013
P2, N=52, Completed, Sponsor: Dr Andrea Rossetti
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion: Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer (clinicaltrials.gov) - Apr 29, 2013
P1, N=60, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial initiation date, Adverse events: Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer (clinicaltrials.gov) - Apr 8, 2013
P2, N=16, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Initiation date: Feb 2007 --> Jun 2007
- RG4733 / Roche
Enrollment closed, Combination therapy: RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Mar 17, 2013
P1, N=24, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Feb 2007 --> Jun 2007 Recruiting --> Active, not recruiting
- Trial completion, Metastases: Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors (clinicaltrials.gov) - Feb 14, 2013
P1/2, N=0, Completed, Sponsor: Duke University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial termination, Surgery, Tumor cell, Biopsy: Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors (clinicaltrials.gov) - Jan 14, 2013
P1, N=46, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated; Administratively complete.
- Trial termination: Yoga Therapy in Treating Patients With Malignant Brain Tumors (clinicaltrials.gov) - Sep 27, 2012
P=N/A, N=9, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
Completed --> Terminated; Administratively complete. Not yet recruiting --> Terminated; Slow Accruals
- Enrollment change: Yoga Therapy in Treating Patients With Malignant Brain Tumors (clinicaltrials.gov) - Sep 27, 2012
P=N/A, N=9, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
Not yet recruiting --> Terminated; Slow Accruals N=20 --> 9
- bortezomib / Generic mfg., temozolomide / Generic mfg.
Enrollment change: Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment (clinicaltrials.gov) - Sep 6, 2012
P1, N=25, Completed, Sponsor: City of Hope Medical Center
N=20 --> 9 N=72 --> 25
- bortezomib / Generic mfg., temozolomide / Generic mfg.
Trial completion: Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment (clinicaltrials.gov) - Sep 6, 2012
P1, N=25, Completed, Sponsor: City of Hope Medical Center
N=72 --> 25 Active, not recruiting --> Completed
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial withdrawal, Combination therapy: A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - May 8, 2012
P1, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Withdrawn
- emvododstat (PTC299) / PTC Therap
Trial suspension: PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors (clinicaltrials.gov) - Apr 16, 2012
P1, N=30, Suspended, Sponsor: Pediatric Brain Tumor Consortium
Completed --> Withdrawn Recruiting --> Suspended
- Trial completion, Surgery: Stereotactic Radiosurgery in Treating Patients With Brain Tumors (clinicaltrials.gov) - Mar 20, 2012
P1, N=0, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Suspended Active, not recruiting --> Completed
- irinotecan / Generic mfg., carmustine / Generic mfg.
Enrollment change: Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors (clinicaltrials.gov) - Mar 12, 2012
P1, N=21, Completed, Sponsor: Darell D. Bigner
Active, not recruiting --> Completed N=41 --> 21
- irinotecan / Generic mfg., carmustine / Generic mfg.
Trial completion: Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors (clinicaltrials.gov) - Mar 12, 2012
P1, N=21, Completed, Sponsor: Darell D. Bigner
N=41 --> 21 Active, not recruiting --> Completed
- Enrollment change: Metabolic Syndrome in Childhood Cancer Survivors (clinicaltrials.gov) - Sep 28, 2011
P=N/A, N=512, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed N=700 --> 512
- Trial completion: Metabolic Syndrome in Childhood Cancer Survivors (clinicaltrials.gov) - Sep 28, 2011
P=N/A, N=512, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
N=700 --> 512 Active, not recruiting --> Completed